AAV with ApoE/hAAT1 promoter driven CreERT2
This AAV expresses CreERT2 driven by a liver ApoE/hAAT1 promoter.
The ApoE/AAT1 chimeric promoter consists of the core promoter from human alpha-1-antitrypsin gene (also known as hAAT1, SERPINA1, A1A, A1AT, AAT, or alpha1AT) and the enhancer/hepatic locus control region (HCR) from the ApoE gene. The ApoE-hAAT1 chimeric promoter is about 0.7Kb and is used for driving gene expression in hepatocytes
A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as “inducible Cre”). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.
Ready-to-use AAV expressing CreERT2 driven by a liver ApoE/hAAT1 promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.